Literature DB >> 24066759

Ibrutinib in relapsed chronic lymphocytic leukemia.

James E Neffendorf, Irina Gout, G Darius Hildebrand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24066759     DOI： 10.1056/NEJMc1309710

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Authors:  Nicolas Acquavella; David Clever; Zhiya Yu; Melody Roelke-Parker; Douglas C Palmer; Liqiang Xi; Holger Pflicke; Yun Ji; Alena Gros; Ken-Ichi Hanada; Ian S Goldlust; Gautam U Mehta; Christopher A Klebanoff; Joseph G Crompton; Madhusudhanan Sukumar; James J Morrow; Zulmarie Franco; Luca Gattinoni; Hui Liu; Ena Wang; Francesco Marincola; David F Stroncek; Chyi-Chia R Lee; Mark Raffeld; Marcus W Bosenberg; Rahul Roychoudhuri; Nicholas P Restifo
Journal:  Cancer Immunol Res       Date:  2014-10-30       Impact factor: 11.151

Review 2.  Ibrutinib: from bench side to clinical implications.

Authors:  Davide Grisafi; Alessandra Maestro; Camilla Grumi; Ludovica Piazzoni; Giampaolo Tirone; Walter Fiore; Roberto Tessari; Valeria Gianardi; Milo Gatti; Francesca Tasca; Daniele Generali; Andrea Ravelli; Francesco Lanza; Francesco Scaglione
Journal:  Med Oncol       Date:  2015-07-30       Impact factor: 3.064

3.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

Review 4.  Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Authors:  Iris de Weerdt; Suzanne M Koopmans; Arnon P Kater; Michel van Gelder
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

Review 5.  Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.

Authors:  Anton M Kolomeyer; Christopher K Hwang; Benjamin J Kim
Journal:  J Med Case Rep       Date:  2018-11-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.